Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis

BACKGROUND: This study aimed to determine the influence of tocilizumab (TCZ) in modifying the clinical and laboratory features of macrophage activation syndrome (MAS) complicating systemic juvenile idiopathic arthritis (s-JIA). Furthermore, we assessed the performance of the 2016 MAS classification...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimizu, Masaki, Mizuta, Mao, Okamoto, Nami, Yasumi, Takahiro, Iwata, Naomi, Umebayashi, Hiroaki, Okura, Yuka, Kinjo, Noriko, Kubota, Tomohiro, Nakagishi, Yasuo, Nishimura, Kenichi, Mohri, Mariko, Yashiro, Masato, Yasumura, Junko, Wakiguchi, Hiroyuki, Mori, Masaaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954608/
https://www.ncbi.nlm.nih.gov/pubmed/31924225
http://dx.doi.org/10.1186/s12969-020-0399-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954608/
https://www.ncbi.nlm.nih.gov/pubmed/31924225
http://dx.doi.org/10.1186/s12969-020-0399-1

Ejemplares similares